Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment.  Blawatt S, Arreola LAG, Magel T, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E.  Addict B...

More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment.  Poulter HL, Walker T, Ahmed D, Moore HJ, Riley F, Towl G, Harris M.  Int J Drug Policy. 2023 Apr 14;116:104025. doi: ...

Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: A context-focused systematic review.  McNair R, Monaghan M, Montgomery P.  Drug Alcohol Depend. 2023 Apr 6;247:109869. doi: 10.1016/j.drugalcde...

Diamorphingestützte Behandlung Opiatabhängiger in Deutschland – Stellungnahme zur Weiterentwicklung  Die Kampagne „100.000 Substituierte bis 2022“ hat in den letzten 18 Monaten mit verschiedenen Maßnahmen und Interventionen einen Beitrag gel...

Feasibility, safety, and acceptability of intranasal heroin-assisted treatment in Switzerland: protocol for a prospective multicentre observational cohort study. Westenberg JN, Meyer M, Strasser J, Krausz M, Dürsteler KM, Falcato L, Vogel M. ...

ADHD Prevalence among Outpatients with Severe Opioid Use Disorder on Daily Intravenous Diamorphine and/or Oral Opioid Maintenance Treatment.  Rohner H, Gaspar N, Rosen H, Ebert T, Kilarski LL, Schrader F, Al Istwani M, Lenz AJ, Dilg C, Welsk...